Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any hypertrophic cardiomyopathy in which the cause of the disease is a mutation in the TTN gene.
Features include always present findings: Thickened heart muscle (hypertrophic cardiomyopathy).
Organ System | Phenotype Count | Example Features |
|---|---|---|
Heart and blood vessels | 1 | Thickened heart muscle (hypertrophic cardiomyopathy) |
Hereditary myopathy with early respiratory failure (HMERF) is a slowly progressive myopathy that typically begins in the third to fifth decades of life .
The usual presenting findings are gait disturbance relating to distal leg weakness or nocturnal respiratory symptoms due to respiratory muscle weakness. Weakness eventually generalizes and affects both proximal and distal muscles.
Muscle weakness can have variability in its distribution and severity, but in general the lower extremities are more affected than the upper extremities. Usually, the earliest and most severely affected muscle is tibialis anterior (ankle dorsiflexion). However, early and predominant hip girdle weakness is also described .
Source: GeneReviews — "Hereditary Myopathy with Early Respiratory Failure"
TTN function has not been fully characterized.
Hypertrophic cardiomyopathy 9 is associated with mutations in the TTN gene on chromosome 2.
Although clinical variability is observed with HMERF-related TTN variants, no relationship between the pathogenic variant and phenotype is evident.
Source: GeneReviews — "Hereditary Myopathy with Early Respiratory Failure"
Penetrance appears to depend on the pathogenic variant. For the common variant, penetrance appears to be complete, although individuals with very late-onset disease have been described (as late as age 71 years); therefore, it is possible that some affected individuals may die from other causes before the disease becomes manifest. The variant appears to have reduced penetrance in at least one family, where only one of two heterozygous family members developed the disease. Because the other pathogenic variants have only been described in a few individuals to date [, , , , , ], data are insufficient to draw conclusions regarding their penetrance; however, current observations suggest complete penetrance.
Source: GeneReviews — "Hereditary Myopathy with Early Respiratory Failure"
Hereditary myopathy with early respiratory failure (HMERF) is a slowly progressive myopathy with typical onset in adulthood. The diagnosis of this rare disorder is not supported by any formal diagnostic criteria at this time.
Diagnosis of hereditary myopathy with early respiratory failure (HMERF) should be suspected in individuals with the following:
Source: GeneReviews — "Hereditary Myopathy with Early Respiratory Failure"
Table 2. Disorders to Consider in the Differential Diagnosis of Hereditary Myopathy with Early Respiratory Failure
Disorder | Gene(s) | MOI | Clinical Features of Differential Disorder |
|---|---|---|---|
Amyotrophic lateral sclerosis | 30 genes1 | ADARXL | Presents w/respiratory failure in ~3% of cases2 |
Characteristic neurophysiologic abnormalities Facioscapulohumeral muscular dystrophy (FSHD) | DNMT3BSMCHD13 |
Genetic testing for TTN is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hypertrophic cardiomyopathy 9 has been reported in the published literature.
No approved treatments are currently available for hypertrophic cardiomyopathy 9. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with hereditary myopathy with early respiratory failure (HMERF), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 3. Recommended Evaluations Following Initial Diagnosis in Individuals with HMERF
System/Concern | Evaluation | Comment |
|---|---|---|
Neuromuscular | Neuromuscular assessment by neurologist w/expertise in inherited muscle disorders | PT |
Respiratory | Assess pulmonary function need for nocturnal ventilator support. | Miscellaneous/ |
Other | Consultation w/clinical geneticist /or genetic counselor | To incl genetic counseling Social services consultation |
Treatment of Manifestations in Individuals with HMERF Manifestation/Concern | Treatment | Considerations/Other |
Distal leg weakness | Ankle-foot orthoses | To optimize independent ambulation Other mobility aids such as canes, walkers, or wheelchairs |
Source: GeneReviews — "Hereditary Myopathy with Early Respiratory Failure"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Hereditary Myopathy with Early Respiratory Failure"
View trials for hypertrophic cardiomyopathy 9
No specific guidelines are in place for surveillance of this disorder; general recommendations are provided in .
Table 5.
Recommended Surveillance for Individuals with HMERF
System/Concern | Evaluation | Frequency
| Reassessment of muscle strength clinical status w/neurologist who can coordinate any additional required services | Annually
| Pulmonary function testing | Every 6-12 mos or guided by individual findings
Source: GeneReviews — "Hereditary Myopathy with Early Respiratory Failure"
Phenotype severity distribution: 1 always present feature.
No clinical trials have been registered for hypertrophic cardiomyopathy 9.
235 publications have been identified in PubMed for hypertrophic cardiomyopathy 9. Kisho has analyzed 169 by research type. Research spans Epidemiology / Natural History (30%), Clinical Trial Publication (24%), and Review / Meta-Analysis (16%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 51 | 30% |
Clinical study results | 41 | 24% |
Research summaries | 27 | 16% |
Laboratory research | 22 | 13% |
Testing and diagnosis research | 19 | 11% |
Patient case studies | 4 | 2% |
New treatment approaches | 3 | 2% |
Other research | 2 | 1% |
Gkizas C (2026). [PMID: 40945993](https://pubmed.ncbi.nlm.nih.gov/40945993/). *Diagn Interv Imaging*. [Diagnostic / Biomarker]
Ibrahim M (2026). [PMID: 41641607](https://pubmed.ncbi.nlm.nih.gov/41641607/). *Crit Pathw Cardiol*. [Review / Meta-Analysis]
Österberg AW (2026). [PMID: 40472950](https://pubmed.ncbi.nlm.nih.gov/40472950/). *Heart Rhythm*. [Epidemiology / Natural History]
Tower-Rader A (2026). [PMID: 41780565](https://pubmed.ncbi.nlm.nih.gov/41780565/). *Eur Heart J*. [Clinical Trial Publication]
Tang Y (2026). [PMID: 41706079](https://pubmed.ncbi.nlm.nih.gov/41706079/). *JACC Cardiovasc Imaging*. [Diagnostic / Biomarker]
Dulal D (2026). [PMID: 41004619](https://pubmed.ncbi.nlm.nih.gov/41004619/). *Eur Heart J Qual Care Clin Outcomes*. [Epidemiology / Natural History]
Xu M (2026). [PMID: 41726140](https://pubmed.ncbi.nlm.nih.gov/41726140/). *Open Med (Wars)*. [Case Report / Case Series]
Dinesen RB (2026). [PMID: 42054027](https://pubmed.ncbi.nlm.nih.gov/42054027/). *JAMA Netw Open*. [Diagnostic / Biomarker]
Zhu C (2026). [PMID: 40368289](https://pubmed.ncbi.nlm.nih.gov/40368289/). *Heart Rhythm*. [Clinical Trial Publication]
Grinberg T (2026). [PMID: 41015143](https://pubmed.ncbi.nlm.nih.gov/41015143/). *Am J Med*. [Basic Science / Preclinical]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 6:50 AM UTC
Online Mendelian Inheritance in Man
Typically presents w/weakness of facial proximal arm muscles (esp shoulder hip girdle); Highly variable disease severity |
GAA | AR | Proximal muscle weakness; Respiratory insufficiency; Early diaphragmatic weakness while still ambulant | Pathologic findings |
Muscle MRI abnormalities Limb-girdle muscular dystrophy type 2(LGMD2; OMIM PS253600) | ~29 genes4 | AR | Weakness wasting restricted to limb musculature (proximal distal); Subtypes LGMD2I (FKRP) the sarcogylcanopathies (LGMD2C-LGMD2F) affect the respiratory muscles early in disease course.5 |
PYROXD1 | ADAR | Significant overlap in clinical, MRI, pathologic features w/HMERF; some individuals w/HMERF meet diagnostic criteria for MFM on muscle biopsy. | — |
Some pathology findings may be specific to HMERF (necklace inclusions, cheetah-skin aggregates). Myotonic dystrophy type 1(DM1) | DMPK8 | AD | Highly variable muscle disease; May present w/distal muscle weakness respiratory muscle involvement; Variable multisystem features incl: myotonia; cataracts; cognitive deficits; cardiac arrhythmia; endocrine GI dysfunction Oculopharyn-godistal myopathy 1 (OMIM 164310) |
LRP12 | ADAR | Early diaphragmatic weakness while still ambulant | Ocular, facial, pharyngeal weakness |
Myasthenia gravis | NA | NA | May present w/respiratory failure skeletal muscle weakness9 |
Source: GeneReviews — "Hereditary Myopathy with Early Respiratory Failure"
Inactivity
Exercises activities suggested by PT consultation |
To prevent continued loss of physical function |
Nocturnal hypoventilation | Noninvasive ventilation w/BiPAP or CPAP | — |
Respiratory failure | Mechanical ventilatory support as needed | — |
susceptibility to respiratory tract infections | Influenza vaccination | — |
Gradually progressive nature of this disease | OT social services support | BiPAP = bilevel positive airway pressure; CPAP = continuous positive airway pressure; OT = occupational therapy; PT = physical therapy Surveillance No specific guidelines are in place for surveillance of this disorder; general recommendations are provided in . Table 5. |
Recommended Surveillance for Individuals with HMERF System/Concern | Evaluation | Frequency |
Neuromuscular | Reassessment of muscle strength clinical status w/neurologist who can coordinate any additional required services | Annually |
Respiratory | Pulmonary function testing | Every 6-12 mos or guided by individual findings Evaluation of Relatives at Risk See for issues related to testing of at-risk relatives for genetic counseling purposes. Information is insufficient to determine if particular issues in HMERF relate to pregnancy. |
AI-curated news mentioning hypertrophic cardiomyopathy 9
Updated Sep 15, 2026
A study identifies natural missplicing events exacerbated by a deep-intronic variant in the MYBPC3 gene as a cause of hypertrophic cardiomyopathy. This discovery enhances understanding of the genetic mechanisms underlying this condition.
A recent study highlights left atrium myocardial remodeling as a prognostic marker in pediatric hypertrophic cardiomyopathy, utilizing CMR feature tracking. This research could enhance monitoring and treatment strategies for affected children.
A new care pathway has been established for diagnosing and managing patients with hypertrophic phenotype in the Marche Region, as reported by the Marche Cardiomyopathies Network. This initiative aims to improve patient outcomes through a structured approach.
Braveheart Bio, Attovia Therapeutics, and Vogenx are preparing for IPOs to enter competitive markets in hypertrophic cardiomyopathy and cardiometabolic diseases. Braveheart aims to rival Bristol Myers Squibb, while Attovia targets Sanofi and Regeneron's Dupixent.
Servier has entered a $2.65 billion deal with Edgewise Therapeutics, allowing Edgewise to pivot towards cardiovascular programs, including EDG-7500 for hypertrophic cardiomyopathy. This non-dilutive capital will enable Edgewise to advance its pipeline significantly.